NEW YORK--(EON: Enhanced Online News)--Levi & Korsinsky announces it has commenced an investigation of TherapeuticsMD, Inc. (NYSEMKT: TXMD). On April 10, 2017, TherapeuticsMD announced receipt of a letter from the U.S. Food and Drug Administration stating that its ongoing review of the Company’s New Drug Application (NDA) for TX-004HR has discovered “deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.” Following this news, shares of TherapeuticsMD were down more than 17% on intraday trading on April 10, 2017. To obtain additional information, go to:
“deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.”
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.